Study Finds Sharp Drop in FDA Inspections of Drug Manufacturing Facilities Since Pandemic Began

The number of inspections of drug manufacturing facilities that the Food and Drug Administration (FDA) was able to carry out both in the United States and abroad plummeted during the COVID-19 pandemic, according to the findings of a new study.

Researchers analyzed FDA inspection data, which was acquired through Freedom of Information Act requests, from the period 2012–2022 across China, Europe, India, Latin America, and other foreign nations.

They found "steep declines in both foreign and domestic inspections in 2020" following lockdowns and travel restrictions implemented after the pandemic first erupted.

Read Full Article Here